Pulmonary oedema (edema) is an abnormal build up of fluid in the lungs, which leads to swelling. Pulmonary oedema is usually caused by heart failure. As the heart fails, pressure in the veins going through the lungs starts to rise. As the pressure in these blood vessels increases, fluid is pushed into the air spaces (alveoli) in the lungs. This fluid interrupts normal oxygen movement through the lungs, resulting in shortness of breath. Pulmonary oedema may be caused by damage directly to the lung, such as that caused by poisonous gas or severe infection. Lung damage with a buildup of body fluid is also seen in kidney failure. Pulmonary oedema may also be a complication of a heart attack, leaking or narrowed heart valves (mitral or aortic valves), or any disease of the heart that results in weakening or stiffening of the heart muscle (cardiomyopathy).
As one of the most common malignant tumors, gastric cancer occupies the second leading cause of cancer-related deaths worldwide with an increasing trend.
Deltex Medical, the global leader in Oesophageal Doppler Monitoring, today announced the results of the largest randomized controlled trial to date of its proprietary fluid management and cardiac output monitoring system.
The aim of these guidelines is to standardize data capture in this area of research and thereby guarantee and indeed improve the quality of clinical research. Scientists from Eurac Research led the evaluation and coordinated the group of experts.
The optimal treatment for heart attack patients will be debated at Acute Cardiovascular Care 2018. The annual congress of the Acute Cardiovascular Care Association, a registered branch of the European Society of Cardiology, will be held 3 to 5 March at the MiCo Milano Congressi in Milan, Italy.
The human protein, prohibitin, may be used by the virus to enter motor neurons and cause the neurological complications of hand, foot and mouth disease.
Severe enterovirus 71 neurological disease in children predominantly involves the spinal cord and brainstem and can be quickly recognised using the World Health Organisation classification of clinicoradiological syndromes, study findings suggest.
United Therapeutics Corporation announced today that the European Commission (EC) has granted Marketing Authorisation for Unituxin (dinutuximab) for the treatment of high-risk neuroblastoma in patients aged 12 months to 17 years, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and autologous stem cell transplantation (ASCT).
Endurance athletes taking part in triathlons are at risk of the potentially life-threatening condition of swimming-induced pulmonary oedema. Cardiologists from Musgrove Park Hospital, Taunton, writing in the Journal of the Royal Society of Medicine, say the condition, which causes an excess collection of watery fluid in the lungs, is likely to become more common with the increase in participation in endurance sports.
GlaxoSmithKline plc and Genmab A/S announced today that the U.S. Food and Drug Administration (FDA) has approved a Supplemental Biologic License Application (sBLA) for the use of Arzerra® (ofatumumab), a CD20-directed cytolytic monoclonal antibody, in combination with chlorambucil for the treatment of previously untreated patients with chronic lymphocytic leukaemia (CLL) for whom fludarabine-based therapy is considered inappropriate.
The first test to identify acute mountain sickness has been developed by a team of researchers in Italy and France and is presented today at EuroEcho-Imaging 2013. The test could revolutionise trekking and climbing by predicting who will develop the potentially deadly condition so they can avoid high altitudes, ascend more gradually or take preventative medication.
Scientists at the European Molecular Biology Laboratory (EMBL) in Heidelberg and Regensburg University, both in Germany, and the University of Lisboa, in Portugal, have discovered a promising potential drug target for cystic fibrosis.
Martindale Pharma, a leader in the manufacture and supply of specialty pharmaceuticals, is pleased to announce the UK launch of Prenoxad Injection, the world's first licensed emergency treatment for acute opioid related overdose for use at home or other non-medical settings.
A new study has found evidence that marathon running could trigger pulmonary oedema, where fluid builds up in the lungs.
The National Food Institute, Technical University of Denmark has assessed the possible toxic effects of eating ramson, which in recent years has become a popular plant to gather and eat in Denmark. As such, ramson does not contain any substances that are toxic for humans, but they can be confused with poisonous plants. In particular, before flowering, ramson leaves can be confused with autumn crocus and lily of the valley. Several cases of poisoning have been reported in other European countries with fatal consequences as a result of this confusion.
The need for long term studies to establish the best means of treating Diabetes, was underlined by Prof John Cleland from the University of Hull at the ESC Congress in Munich. Prof Cleland listed the latest treatment available for patients and voiced his concern about the side-effects and efficacy of available anti-diabetic drugs.
As of April 29 a total of 1,884 cases including 20 deaths of hand, foot and mouth disease (HFMD) due to enterovirus (EV-71) have been reported among infants and young children. The 20 deaths are in Fuyang city in Anhui Province, China.
Acute cardiogenic pulmonary oedema, or "fluid on the lung", is a common, extremely distressing and often fatal condition that is a major consumer of health care resources. The aim of the 3CPO trial was to establish whether high-pressure oxygen, given by a simple facemask, could help reduce the death rate in patients with this condition.
Experts at the University are studying an illness known as HAPE (high altitude pulmonary oedema), which causes fluid to build up in the lungs can and can occur from as low as 2,500 metres, affecting people of all age groups and fitness levels.
Thalidomide, famous in the 60's because of limb deformities in babies born to women who had taken it for morning sickness, was withdrawn in 1961. Now doctors say it could be used as a treatment for cancer.